Scinai Immunotherapeutics
SCNI
9 hedge funds and large institutions have $4.43M invested in Scinai Immunotherapeutics in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
84% more capital invested
Capital invested by funds: $2.41M → $4.43M (+$2.02M)
13% more funds holding
Funds holding: 8 → 9 (+1)
0.38% more ownership
Funds ownership: 2.2% → 2.58% (+0.38%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mariner
Overland Park,
Kansas
|
+$350K |
| 2 |
Renaissance Technologies
New York
|
+$86K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.14K |
SCNI Hedge Fund Activity: Q4 2019 in Review
9 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q4 2019, worth a combined $4.43M — up 84% from $2.41M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SCNI positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Mariner, opening a new position worth an estimated $350K. The largest seller was Deutsche Bank, exiting entirely with an estimated $6.14K sold.
- 9 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q4 2019, up from 8 in Q3 2019.
- Funds reported $4.43M of Scinai Immunotherapeutics stock for Q4 2019, up 84% quarter-over-quarter.
- 2 funds opened new Scinai Immunotherapeutics positions in Q4 2019 and 1 closed out, a net change of +1 holder.
- The largest Scinai Immunotherapeutics buyer in Q4 2019 was Mariner, an estimated $350K added.
- The largest Scinai Immunotherapeutics seller in Q4 2019 was Deutsche Bank, an estimated $6.14K sold.
Based on aggregated 13F filings for Q4 2019.